Skip to content

About Us
Our Science
Pipeline
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs

About Us
Our Science
Pipeline
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs

About Us
Our Science
Pipeline
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs

About Us
Our Science
Pipeline
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs

News

Select Year
Clinical Trials
Search …

November 3, 2021

Oncolytics Biotech® Doses First Patient in Phase 1/2 GOBLET Study Evaluating Pelareorep-anti-PD-L1 Combination Therapies in Gastrointestinal Cancers

October 19, 2021

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights

October 14, 2021

Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer

September 20, 2021

Oncolytics Biotech® Announces Preclinical Data Demonstrating the Synergistic Immunotherapeutic Effects of Pelareorep Combined with Radiotherapy

August 6, 2021

Oncolytics Biotech® to Participate in Virtual Fireside Chat at the Canaccord Genuity 41st Annual Growth Conference

August 6, 2021

Oncolytics Biotech® Reports 2021 Second Quarter Development Highlights and Financial Results

July 22, 2021

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights

June 30, 2021

Oncolytics Biotech® to Present at the Ladenburg Thalmann Healthcare Conference

May 20, 2021

Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer

May 13, 2021

Oncolytics Biotech® to Participate in Virtual Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference

Page 17 of 71

Investor Relations Contact

Jon Patton
Director of Investor Relations & Communication
Email: jpatton@oncolytics.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy

Loading...

4350 Executive Drive
Suite 325
San Diego, CA 92121
info@oncolyticsbiotech.com

Company

Our Mission
Leadership
Board of Directors
Careers
Contact

Science

Our Science
Pipeline
Resources

Investors

Overview
News
Events
Stock Information
Filings
Corporate Governance
FAQs

Privacy Policy Accessibility Cookie Policy Disclaimer Manage Consent

Copyright © 2026 Oncolytics Biotech Inc.